Rylaze

asparaginase erwinia chrysanthemi (recombinant)-rywn

Approval

ApplicationBLA 761179
Approval dateJun 30, 2021
Approval year2021
SponsorJazz Pharms

FDA-approved use

To treat acute lymphoblastic leukemia and lymphoblastic lymphoma in patients who are allergic to E. coli-derived asparaginase products, as a component of a chemotherapy regimen

Approval package

Query with Claude

The fda-analyst skill answers natural-language questions about this approval by fetching the relevant FDA review PDFs at query time.

git clone https://github.com/cbetz/trove
cp -r trove/skills/fda-analyst ~/.claude/skills/

Example prompts for Rylaze: